
- /
- Supported exchanges
- / F
Fate Therapeutics Inc (F6T F) stock market data APIs
Fate Therapeutics Inc Financial Data Overview
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Fate Therapeutics Inc data using free add-ons & libraries
Get Fate Therapeutics Inc Fundamental Data
Fate Therapeutics Inc Fundamental data includes:
- Net Revenue: 13 447 K
- EBITDA: -164 668 992
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-04
- EPS/Forecast: -0.53
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Fate Therapeutics Inc News

Fate Therapeutics (FATE) Soars 25.4%: Is Further Upside Left in the Stock?
Fate Therapeutics (FATE) shares rallied 25.4% in the last trading session to close at $5.72. This move can be attributable to notable volume with a higher number of shares being traded than in a typic...


Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
Fate Therapeutics, Inc. iPSC-derived CAR T-cell Product Candidate Incorporates Seven Synthetic Controls of Cell Function including a Novel HER2-targeted Antigen Binding Domain Phase 1 Study is Being...

Fate Therapeutics Insiders US$207k Short Of Breakeven On Stock Purchase
Insiders who bought US$698.1k worth of Fate Therapeutics, Inc. (NASDAQ:FATE) stock in the last year have seen some of their losses recouped as the stock gained 18% last week. The purchase, however, ha...

Fate Therapeutics (FATE) Upgraded to Buy: Here's Why
Fate Therapeutics (FATE) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.